Literature DB >> 29422597

From genetics to the clinic: a translational perspective on follicular lymphoma.

Sarah Huet1,2,3, Pierre Sujobert1,2,4, Gilles Salles1,2,4.   

Abstract

Follicular lymphoma (FL) is the most frequent indolent B cell lymphoma and is still considered to be incurable. In recent years, whole-exome sequencing studies of large cohorts of patients have greatly improved our knowledge of the FL mutational landscape. Moreover, the prolonged evolution of this disease has enabled some insights regarding the early pre-lymphoma lesions as well as the clonal evolution after treatment, allowing an evolutionary perspective on lymphomagenesis. Deciphering the earliest initiating lesions and identifying the molecular alterations leading to disease progression currently represent important goals; accomplishing these could help identify the most relevant targets for precision therapy.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29422597     DOI： 10.1038/nrc.2017.127

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  187 in total

1.  Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.

Authors:  Kilannin Krysiak; Felicia Gomez; Brian S White; Matthew Matlock; Christopher A Miller; Lee Trani; Catrina C Fronick; Robert S Fulton; Friederike Kreisel; Amanda F Cashen; Kenneth R Carson; Melissa M Berrien-Elliott; Nancy L Bartlett; Malachi Griffith; Obi L Griffith; Todd A Fehniger
Journal:  Blood       Date:  2016-11-14       Impact factor: 22.113

2.  Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma.

Authors:  D De Jong; B M Voetdijk; G C Beverstock; G J van Ommen; R Willemze; P M Kluin
Journal:  N Engl J Med       Date:  1988-05-26       Impact factor: 91.245

Review 3.  The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target.

Authors:  Mariano G Cardenas; Erin Oswald; Wenbo Yu; Fengtian Xue; Alexander D MacKerell; Ari M Melnick
Journal:  Clin Cancer Res       Date:  2016-11-23       Impact factor: 12.531

4.  Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice.

Authors:  Idoia García-Ramírez; Saber Tadros; Inés González-Herrero; Alberto Martín-Lorenzo; Guillermo Rodríguez-Hernández; Dalia Moore; Lucía Ruiz-Roca; Oscar Blanco; Diego Alonso-López; Javier De Las Rivas; Keenan Hartert; Romain Duval; David Klinkebiel; Martin Bast; Julie Vose; Matthew Lunning; Kai Fu; Timothy Greiner; Fernando Rodrigues-Lima; Rafael Jiménez; Francisco Javier García Criado; María Begoña García Cenador; Paul Brindle; Carolina Vicente-Dueñas; Ash Alizadeh; Isidro Sánchez-García; Michael R Green
Journal:  Blood       Date:  2017-03-13       Impact factor: 22.113

5.  Follicular lymphoma-like B cells of uncertain significance (in situ follicular lymphoma) may infrequently progress, but precedes follicular lymphoma, is associated with other overt lymphomas and mimics follicular lymphoma in flow cytometric studies.

Authors:  Raju K Pillai; Urvashi Surti; Steven H Swerdlow
Journal:  Haematologica       Date:  2013-07-05       Impact factor: 9.941

6.  Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte.

Authors:  Emmanuel Bachy; Pauline Brice; Richard Delarue; Nicole Brousse; Corinne Haioun; Steven Le Gouill; Alain Delmer; Dominique Bordessoule; Hervé Tilly; Bernadette Corront; Christian Allard; Charles Foussard; André Bosly; Bertrand Coiffier; Christian Gisselbrecht; Philippe Solal-Celigny; Gilles Salles
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

7.  Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression.

Authors:  Stéphanie Sungalee; Emilie Mamessier; Ester Morgado; Emilie Grégoire; Philip Z Brohawn; Christopher A Morehouse; Nathalie Jouve; Céline Monvoisin; Cédric Menard; Guilhaume Debroas; Mustapha Faroudi; Violaine Mechin; Jean-Marc Navarro; Charlotte Drevet; Franziska C Eberle; Lionel Chasson; Fannie Baudimont; Stéphane J Mancini; Julie Tellier; Jean-Michel Picquenot; Rachel Kelly; Paolo Vineis; Philippe Ruminy; Bruno Chetaille; Elaine S Jaffe; Claudine Schiff; Jean Hardwigsen; David A Tice; Brandon W Higgs; Karin Tarte; Bertrand Nadel; Sandrine Roulland
Journal:  J Clin Invest       Date:  2014-11-10       Impact factor: 14.808

8.  Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.

Authors:  Matthew J Maurer; Emmanuel Bachy; Hervé Ghesquières; Stephen M Ansell; Grzegorz S Nowakowski; Carrie A Thompson; David J Inwards; Cristine Allmer; Catherine Chassagne-Clément; Emmanuelle Nicolas-Virelizier; Catherine Sebban; Laure Lebras; Clementine Sarkozy; William R Macon; Andrew L Feldman; Sergei I Syrbu; Alexandra Traverse-Glehan; Bertrand Coiffier; Susan L Slager; George J Weiner; Thomas E Witzig; Thomas M Habermann; Gilles Salles; James R Cerhan; Brian K Link
Journal:  Am J Hematol       Date:  2016-09-03       Impact factor: 10.047

9.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.

Authors:  Wendy Béguelin; Relja Popovic; Matt Teater; Yanwen Jiang; Karen L Bunting; Monica Rosen; Hao Shen; Shao Ning Yang; Ling Wang; Teresa Ezponda; Eva Martinez-Garcia; Haikuo Zhang; Yupeng Zheng; Sharad K Verma; Michael T McCabe; Heidi M Ott; Glenn S Van Aller; Ryan G Kruger; Yan Liu; Charles F McHugh; David W Scott; Young Rock Chung; Neil Kelleher; Rita Shaknovich; Caretha L Creasy; Randy D Gascoyne; Kwok-Kin Wong; Leandro Cerchietti; Ross L Levine; Omar Abdel-Wahab; Jonathan D Licht; Olivier Elemento; Ari M Melnick
Journal:  Cancer Cell       Date:  2013-05-13       Impact factor: 31.743

10.  Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma.

Authors:  Abdulwahab J Al-Tourah; Karamjit K Gill; Mukesh Chhanabhai; Paul J Hoskins; Richard J Klasa; Kerry J Savage; Laurie H Sehn; Tamara N Shenkier; Randy D Gascoyne; Joseph M Connors
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544
View more
  33 in total

Review 1.  Sequencing of therapies in relapsed follicular lymphoma.

Authors:  Loretta J Nastoupil; Christopher R Flowers; John P Leonard
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment.

Authors:  Daniele Grimaldi; Elisa Genuardi; Martina Ferrante; Simone Ferrero; Marco Ladetto
Journal:  Curr Treat Options Oncol       Date:  2018-11-06

3.  Coactivation of NF-κB and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion.

Authors:  Yan Xiu; Qianze Dong; Lin Fu; Aaron Bossler; Xiaobing Tang; Brendan Boyce; Nicholas Borcherding; Mariah Leidinger; José Luis Sardina; Hai-Hui Xue; Qingchang Li; Andrew Feldman; Iannis Aifantis; Francesco Boccalatte; Lili Wang; Meiling Jin; Joseph Khoury; Wei Wang; Shimin Hu; Youzhong Yuan; Endi Wang; Ji Yuan; Siegfried Janz; John Colgan; Hasem Habelhah; Thomas Waldschmidt; Markus Müschen; Adam Bagg; Benjamin Darbro; Chen Zhao
Journal:  Blood       Date:  2020-01-09       Impact factor: 22.113

4.  Oncogenic Rag GTPase signaling enhances B cell activation and drives follicular lymphoma sensitive to pharmacological inhibition of mTOR.

Authors:  Ana Ortega-Molina; Nerea Deleyto-Seldas; Joaquim Carreras; Alba Sanz; Cristina Lebrero-Fernández; Camino Menéndez; Andrew Vandenberg; Beatriz Fernández-Ruiz; Leyre Marín-Arraiza; Celia de la Calle Arregui; Ana Belén Plata-Gómez; Eduardo Caleiras; Alba de Martino; Nuria Martínez-Martín; Kevin Troulé; Elena Piñeiro-Yáñez; Naoya Nakamura; Shamzah Araf; Gabriel D Victora; Jessica Okosun; Jude Fitzgibbon; Alejo Efeyan
Journal:  Nat Metab       Date:  2019-08-19

Review 5.  The Emerging Role of Liquid Biopsies in Lymphoproliferative Disorders.

Authors:  Jennifer Crombie; Philippe Armand
Journal:  Curr Hematol Malig Rep       Date:  2019-02       Impact factor: 3.952

Review 6.  How do I sequence therapy for follicular lymphoma?

Authors:  Gilles Salles
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

7.  Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma.

Authors:  Cédric Rossi; Pauline Gravelle; Emilie Decaup; Julie Bordenave; Mary Poupot; Marie Tosolini; Don-Marc Franchini; Camille Laurent; Renaud Morin; Jean-Michel Lagarde; Loïc Ysebaert; Laetitia Ligat; Christine Jean; Ariel Savina; Christian Klein; Alba Matas Céspedes; Patricia Perez-Galan; Jean-Jacques Fournié; Christine Bezombes
Journal:  Oncoimmunology       Date:  2018-12-17       Impact factor: 8.110

8.  PI3Kδ inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax.

Authors:  Neus Serrat; Martina Guerrero-Hernández; Alba Matas-Céspedes; Anella Yahiaoui; Juan G Valero; Ferran Nadeu; Guillem Clot; Miriam Di Re; Marc Corbera-Bellalta; Laura Magnano; Alfredo Rivas-Delgado; Anna Enjuanes; Silvia Beà; Maria C Cid; Elías Campo; Joan Montero; Daniel J Hodson; Armando López-Guillermo; Dolors Colomer; Stacey Tannheimer; Patricia Pérez-Galán
Journal:  Blood Adv       Date:  2020-09-08

Review 9.  T follicular helper cells in germinal center B cell selection and lymphomagenesis.

Authors:  Michelle A Mintz; Jason G Cyster
Journal:  Immunol Rev       Date:  2020-05-15       Impact factor: 12.988

Review 10.  B Cell Responses: Cell Interaction Dynamics and Decisions.

Authors:  Jason G Cyster; Christopher D C Allen
Journal:  Cell       Date:  2019-04-18       Impact factor: 41.582
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.